Summary

The 7 major Tourette syndrome markets reached a value of US$ 1,818.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2,710.2 Million by 2034, exhibiting a growth rate (CAGR) of 3.7% during 2024-2034.

The Tourette syndrome market has been comprehensively analyzed in IMARC's new report titled "Tourette Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Tourette syndrome (TS) is a neurological disorder characterized by repetitive, involuntary movements, and vocalizations called tics. These tics can be either motor tics or vocal tics, including eye blinking, facial grimacing, shoulder shrugging, throat clearing, grunting, etc. Tourette syndrome often begins in childhood and continues into adulthood, although the severity of symptoms may decrease over time for some individuals. In addition to tics, they may also experience other conditions, such as attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD). The diagnosis of the ailment is based on a thorough evaluation of the patient's symptoms and medical history. To be diagnosed with TS, an individual must have both motor and vocal tics that have been present for at least one year, with onset before age 18. The tics must be involuntary and not the result of other medical conditions, such as a medication side effect or another neurological disorder. The healthcare professional may also use diagnostic tools, including imaging studies or blood tests, to rule out other possible causes of the symptoms.

The increasing prevalence of inherited neurological disorders and the rising cases of delivery complications, such as meconium-stained amniotic fluid and premature rupture of the membranes, are primarily driving the Tourette syndrome market. Moreover, the escalating utilization of medications, including antipsychotics and alpha-adrenergic agonists, to help reduce the frequency and severity of tics, as well as treat any co-occurring conditions, such as OCD and ADHD, is also bolstering the market growth. Besides this, the widespread adoption of deep brain stimulation (DBS) as a treatment option for Tourette syndrome since it assists in regulating abnormal brain activity associated with tics is further creating a positive outlook for the market. Additionally, several key players are making extensive investments in research activities to introduce novel therapies for Tourette syndrome, including new medications and non-invasive brain stimulation techniques. This, in turn, is acting as another significant growth-inducing factor. Apart from this, the launch of numerous initiatives by government bodies aimed at supporting research and development and improving access to care for individuals with Tourette syndrome is also augmenting the market growth. These initiatives are helping to increase awareness, improve diagnosis rates, and expand treatment options. Furthermore, the emerging popularity of behavioral therapies, such as cognitive-behavioral therapy (CBT) and habit reversal therapy (HRT), which assist patients in identifying and replacing tic-related behaviors with more adaptive ones, is expected to drive the Tourette syndrome market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Tourette syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Tourette syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Tourette syndrome market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Tourette syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Tourette syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Tourette syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the Tourette syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Tourette syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Tourette syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Tourette syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of Tourette syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Tourette syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Tourette syndrome across the seven major markets?
What is the size of the Tourette syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Tourette syndrome?
What will be the growth rate of patients across the seven major markets?

Tourette Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Tourette syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Tourette syndrome market?
What are the key regulatory events related to the Tourette syndrome market?
What is the structure of clinical trial landscape by status related to the Tourette syndrome market?
What is the structure of clinical trial landscape by phase related to the Tourette syndrome market?
What is the structure of clinical trial landscape by route of administration related to the Tourette syndrome market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Tourette Syndrome - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034​)
4.4 Market Overview (2018-2023) and Forecast (2024-2034​)
4.5 Competitive Intelligence

5 Tourette Syndrome - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Tourette Syndrome - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034​)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034​)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034​)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034​)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034​)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034​)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034​)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034​)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)

8 Tourette Syndrome - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Tourette Syndrome - Unmet Needs

10 Tourette Syndrome - Key Endpoints of Treatment

11 Tourette Syndrome - Marketed Products
11.1 List of Tourette Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Abilify (Aripiprazole) - Bristol-Myers Squibb/Otsuka Pharmaceutical
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Haloperidol
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Pimozide
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Tourette Syndrome - Pipeline Drugs
12.1 List of Tourette Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Deutetrabenazine - Teva Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ecopipam - Emalex Biosciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 SCI110 - SciSparc
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Valbenazine - Neurocrine Biosciences
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Tourette Syndrome - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Tourette Syndrome – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Tourette Syndrome - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Tourette Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034​)
15.2.2 Tourette Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034​)
15.3 Market Scenario - United States
15.3.1 Tourette Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034​)
15.3.2 Tourette Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034​)
15.3.3 Tourette Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Tourette Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034​)
15.4.2 Tourette Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034​)
15.4.3 Tourette Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Tourette Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034​)
15.5.2 Tourette Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034​)
15.5.3 Tourette Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Tourette Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034​)
15.6.2 Tourette Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034​)
15.6.3 Tourette Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Tourette Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034​)
15.7.2 Tourette Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034​)
15.7.3 Tourette Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Tourette Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034​)
15.8.2 Tourette Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034​)
15.8.3 Tourette Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Tourette Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034​)
15.9.2 Tourette Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034​)
15.9.3 Tourette Syndrome - Access and Reimbursement Overview

16 Tourette Syndrome - Recent Events and Inputs From Key Opinion Leaders

17 Tourette Syndrome Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Tourette Syndrome Market – Strategic Recommendations

19 Appendix